Fate Therapeutics Inc expected to post a loss of 89 cents a share - Earnings Preview

Fate Therapeutics

01/11/2022 22:15

* Fate Therapeutics Inc  FATE.OQ   FATE.O  is expected
to show a
rise in quarterly revenue when it reports  results on November
3. 
    * The San Diego California-based  company is expected to
report  a
9.8% increase in revenue to $15.626 million from $14.23 million
a year ago, according to the mean estimate from 18 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Fate Therapeutics
Inc is
for a loss of 89 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 19 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Fate
Therapeutics
Inc is $71​, above​ its last closing price of $20.99. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.81       -0.83      -0.79     Beat    4.4
 Mar. 31 2022  -0.77       -0.77      -0.68     Beat    11.1
 Dec. 31 2021  -0.65       -0.67      -0.72     Missed  -8​
 Sep. 30 2021  -0.59       -0.58      -0.45     Beat    22.6
 ​​Jun.        -0.54       -0.53      -0.58     Missed  -10
 30 2021                                                
 Mar. 31 2021  -0.45       -0.43      -0.48     Missed  -10.9​
 Dec. 31 2020  -0.40       -0.39      -0.61     Missed  -55.2
 Sep. 30 2020  -0.36       -0.36      -0.68     Missed  -87.5
 This summary was machine generated November 1 at 22:15 GMT.  All
figures in US dollars  unless otherwise stated